



NEW INDICATION



Now for the treatment of *ROS1*-positive locally advanced or metastatic NSCLC

ROZLYTREK (entrectinib) is indicated for the treatment of patients with *ROS1*-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) not previously treated with crizotinib.

Contact your Roche representative to learn more

| | | | | | | | | |
|-------------|-------------|-----------|--|--|-------------------------|--|------|----------------------------|
| fuelcontent | ROUND | 01 | File Name: 11319703_Rozlytrek_tip-on_6908E20_EN.indd | | Safety: 1.625" x 1.625" | | NAME | CYAN |
| | | | Docket #: 11319703 | | Trim: 1.75" x 1.75" | | | MAGENTA |
| | | | Client: Roche | | Bleed: 1.875" x 1.875" | | | YELLOW |
| | | | | | | | | BLACK |
| | MOD DATE: | Jul 00/20 | Producer: Chris | | VO: / | | | |
| | START DATE: | Jul 03/20 | Artist: fritz | | DIELINE | | | |
| | | | | | | | | THIS IS NOT A COLOUR PROOF |

Please consult the Product Monograph at rochecanada.com/PMs/Rozlytrek/Rozlytrek_PM_E.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, drug interactions, dosing information and conditions of clinical use which has not been discussed in this piece.

The Product Monograph is also available by calling Roche Drug Information at 1-888-762-4388.



Reference: ROZLYTREK Product Monograph. Hoffmann-La Roche Limited. April 30, 2020.

If you require this information in an accessible format, please contact Roche at 1-800-561-1759.

© Copyright 2020, Hoffmann-La Roche Limited
ROZLYTREK® Registered trademark of F. Hoffmann-La Roche AG, used under license



Hoffmann-La Roche Limited
Mississauga, ON L5N 5M8



6908E20